# Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

> **NCT01900496** · PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 6 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Brentuximab vedotin
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01900496
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2018-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900496, "Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01900496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*